Disclosed is the use of a DPP IV inhibitor linagliptin also known as 8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione or 1-[( 4-methyl-quinazolin-2-yl)methyl]-3-methyl-7 -(2-butyn-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine for preparing a medicament for the therapeutic treatment of a physiological functional disorder heart failure. Also disclosed is the combination of linagliptin with another active for the treatment of type 2 diabetes, pre-diabetes or metabolic syndrome. Examples of the other active includes metformin, telmisartan and glitazone. The dosage of linagliptin is 2.5 mg or 5 mg and the dosage is for oral administration.
